What is claimed is ~~Claims~~

1. A method of inactivating lipid-enveloped viruses in biological or biotechnological products or in cell cultures, characterized in that the products or cell cultures are added with a cyclic lipopeptide, salts or esters thereof, or mixtures of same as inactivating agent, and inactivation is performed at room temperature within from 30 minutes up to 2 hours at maximum, wherein

a) the agent is added to said products at a concentration of 1-100 µM when inactivating viruses in the products;

b) the agent is added to the serum-free culture medium at a concentration of 1-65 µM, or to the serum-containing culture medium at a concentration of 10-100 µM, when inactivating viruses in cell cultures.

2. The method of claim 1, characterized in that the virus inactivation in biological or ~~biotechnological~~ products is performed at temperatures higher than room temperature, ~~preferably 30-60°C,~~ within a period of 5-30 min.

3. The method according to claim 1 ~~or 2~~, characterized in that naturally occurring, chemically synthesized lipopeptides, as well as those produced or modified by genetic engineering are used as cyclic lipopeptides.

4. The method according to ~~any of claims 1-3~~ claim 1, characterized in that lipoheptapeptides of general formula I,



(I)

the salts, esters or mixtures thereof are used as lipopeptides, in which formula I, X and Y independently represent the amino acids Leu, Ile or Val, Z represents the amino acids Val or Ala, and C_{10-12} represents a linear or branched, saturated alkyl chain.

5. The method according to claim 4, characterized in that ~~compounds of general formula I with~~ C_{10-12} is a C_{11} alkyl or C_{12} alkyl ~~are used~~.

6. The method according to claim 4 ~~or 5~~, characterized in that esters of the compounds of general formula I, ~~preferably monoesters~~ are employed.

7. The method according to ~~any of claims 4-6~~ claim 4, characterized in that compounds of general formula I are used, wherein X and Y represent Leu, and Z represents Val.

8. The method according to ~~any of claims 4-6~~ claim 4, characterized in that compounds of general formula I are used, wherein X represents Ile or Val.

9. The method according to ~~any of claims 1-8~~ claim 1, characterized in that lipid-enveloped human and non-human animal viruses are inactivated.

10. The method according to ~~any of claims 1-8~~ claim 1, characterized in that herpes viruses, preferably HSV-1, HSV-2, BHV-1, SHV-1, immunodeficiency viruses, preferably HIV-1, HIV-2, SIV_{agm}, the vesicular stomatitis virus (VSV), and the Semliki-Forest virus (SFV) are inactivated.

11. ~~New lipoheptapeptides~~ Lipoheptapeptides of general formula I



(I)

and the salts and esters thereof, in which formula I X and Y independently represent Val or Ile, and Z represents Val.

12. Use of the lipopeptides according to claim 11 for inactivating lipid-enveloped viruses in biological or biotechnological products, or in cell cultures.